Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
June 10, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
May 21, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D.,...
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
May 14, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase...
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
May 08, 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA)...
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
December 03, 2018 07:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle...
Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
August 27, 2018 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE,...
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
July 24, 2018 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients...
Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
May 16, 2018 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125,...
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
February 14, 2018 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 15 Patients with Psoriasis-- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna...
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
October 24, 2017 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis-- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) --...